Skip to Menu Skip to Search Contact Us Global Websites & Languages Skip to Content
Immunoassay

SGS Life Science Services, the leading pharmaceutical clinical and bioanalytical contract solutions provider, today announced that it has invested in additional modules for its COBAS 6000 analysis system, to increase its biomarker analytical capabilities. SGS has made this further investment in response to client demand and now possesses comprehensive biomarker testing capabilities across a number of instrument platforms, for both multiplexing and single analyte testing.

 

The Roche COBAS system 6000, introduced in June 2014 at the SGS facility in Poitiers, France, was initially equipped with the clinical chemistry module for small molecule and analyte testing. The recent expansion of capabilities involves the addition of an immunoassay module which can be used for the quantification of a large number of cytokines, hormones, and other biomarkers of various disease areas such as oncology, endocrinology, sepsis, anemia and cardiac disease. This new module expands and complements the existing platforms and adds further capabilities for drug development supporting biomarkers for various applications, such as risk assessment, safety, and efficacy testing.

Both modules are now online and offer a number of advantages for pharmaceutical companies looking to support large biomarker analysis projects, both in big batches and online analysis of smaller batches. The testing process is fully automated which maintains the integrity of the samples throughout the process, and run times and turnaround times are minimized by the high throughput methods. In addition, the system offers high sensitivity, precision and wide dynamic range, while requiring only small volumes of clinical samples. Additionally, the reagents are thoroughly qualified for lot consistency, minimizing the need for additional validation before the testing of clinical samples.

“It is important for SGS that we continue to adapt and evolve to meet our clients’ needs in this rapidly changing area of the industry,” commented Alain Renoux, Director of SGS Life Science Services, Poitiers. “By investing in new areas across our global network, both scientifically and geographically, we continue to underpin our commitment to our existing clients and increase our appeal to new markets.”

The announcement follows SGS’ recent investment in the analytical services offered by its laboratory in West Chester, PA, and in Taunusstein, Germany. The Poitiers facility also recently announced the validation of a novel Meso Scale Discovery (MSD®) multiplex quantification of a panel of inflammatory cytokines. This latter investment complements the services provided through the new COBAS modules.

With 19 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly-owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I to IV clinical trial management and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.

For further information, please contact:

Ferdinand Dabu
Global Marketing Director
Life Science Services
SGS, 75 Passaic Avenue,
Fairfield, NJ 07004, USA
t: +1-973-287-1219
www.sgs.com/lifescience

Richard Kerns
President
NEPR
t. +44 (0)161 728 5880

About SGS

SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognised as the global benchmark for quality and integrity. With more than 80,000 employees, SGS operates a network of over 1,650 offices and laboratories around the world.